CCN2 and systemic sclerosis: Given the key role of CTGF in the development of skin fibrosis in SSc, the goal of this study was to evaluate the efficacy of FG-3019 as a potential therapeutic agent for SSc using a murine model of angiotensin II (Ang II)-induced skin fibrosis [15–17].